Exhibit 10.1


 


WAIVER AND WARRANT EXERCISE AGREEMENT


 


This Warrant Exercise
Agreement (this “Agreement”), dated as of March [ ], 2021, is by and between TD Holdings, Inc., a Delaware corporation
(the “Company”), and the undersigned holder (the “Holder”) of warrants to purchase common
stock of the Company, $0.001 par value per share (the “Common Stock”) issued by the Company, which warrants
were issued on April 15, 2019, as amended (the “April Warrants”), and/or on May 23, 2019 (the “May
Warrants”), exercisable at exercise prices of $2.20 per share and $1.32 per share, respectively (the April Warrants and
May Warrants are collectively referred to as the “Original Warrants”).


 


WHEREAS, the Holder’s
Original Warrants are exercisable into shares of Common Stock represented by a number of shares of Common Stock as set forth on
the Holder’s signature page hereto (the “Warrant Shares”) and are currently registered pursuant to a registration
statement on Form S-3 (File No. 333-239757) which became effective on August 4, 2020 (the “Registration Statement”).


 


NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy
of which are hereby acknowledged, the Holder and the Company agree as follows:


 


ARTICLE I


DEFINITIONS


 


Section 1.1 Definitions.
Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in the Original Warrants. 


 


ARTICLE II


WAIVER AND EXERCISE OF ORIGINAL WARRANTS


 


Section 2.1 Waiver
and Exercise Agreement.


 


In consideration
for the cashless exercise of all of the Original Warrants by the Holder, the Company hereby waives the obligation of the Holder
to pay such portion of the exercise price of each of the Original Warrants in excess of $[ ] per share immediately prior to the
time of exercise of such Original Warrants (the “Waiver”). The parties hereto hereby acknowledge and agree that,
after giving effect to the Waiver, exercise price of each of Original Warrants shall be deemed to be $[ ] per share and the Original
Warrants shall be deemed to have been exercised in a cashless exercise as if the Holder delivered a Notice of Exercise to the Company
as of the date hereof (such shares of Common Stock to be issued in any such cashless exercise, the “Exercised Shares”).
Within two Trading Days of the date hereof, the Company shall delivery the Exercised Shares to the DTC account of the Holder via
the DWAC system as if the Holder had exercised its Original Warrants pursuant to a cashless exercise entitling it to receive the
Exercised Shares and the relevant provisions of the Original Warrants governing delivery of Warrant Shares shall apply to Company’s
obligations to deliver the Exercised Shares hereunder. Notwithstanding anything herein to the contrary, in the event that the Warrant
Exchange would otherwise cause the Holder to exceed the beneficial ownership limitation (the “Beneficial Ownership Limitation”)
in the Original Warrants, the Company shall only issue such number of Exercised Shares to the Holder (as instructed in writing
by the Holder) that would not cause such Holder to exceed the maximum number of Warrant Shares permitted thereunder with the balance
to be held in abeyance until the balance (or portion thereof) may be issued in compliance with such beneficial ownership limitations.
Holder shall provide written notice to the Company promptly when any additional Exercised Shares may be issued in compliance with
the Beneficial Ownership Limitation. The balance of the Exercised Shares shall be issued when the Holder provides notice that the
Holder holds less than the Beneficial Ownership Limitation via The Depository Trust Company Deposit or Withdrawal at Custodian
system (“DWAC”) no later than the 2nd Trading Day following the date of such notice.


 



     


     


    




 


Section 2.2 Participation
in Future Financing.


 


(a) From
the date hereof until the twelve (12) month anniversary of the date hereof, upon any issuance by the Company or any of its Subsidiaries
of Common Stock or Common Stock Equivalents (or a combination of units thereof) (a “Subsequent Financing”),
the Holder shall have the right to participate in the Subsequent Financing up to an amount equal to 25% of the Subsequent Financing,
reflecting the aggregate percentage of the Holder and all Other Holders under Other Warrant Exercise Agreements (the
“Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent Financing.


 


(b) Between
the time period of 4:00 pm (New York City time) and 6:00 pm (New York City time) on the Trading Day immediately prior to the Trading
Day of the expected announcement of the Subsequent Financing (or, if the Trading Day of the expected announcement of the Subsequent
Financing is the first Trading Day following a holiday or a weekend (including a holiday weekend), between the time period of 4:00
pm (New York City time) on the Trading Day immediately prior to such holiday or weekend and 2:00 pm (New York City time) on the
day immediately prior to the Trading Day of the expected announcement of the Subsequent Financing), the Company shall deliver to
the Holder a written notice of the Company’s intention to effect a Subsequent Financing (a “Subsequent Financing
Notice”), which notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount
of proceeds intended to be raised thereunder and the Person or Persons through or with whom such Subsequent Financing is proposed
to be effected and shall include a term sheet and transaction documents relating thereto as an attachment. The Holder shall keep
confidential of the information set forth in the Subsequent Financing Notice and will not be disclosed to anyone other than its
officers, directors and employees. Any confidentiality obligations shall automatically terminate when the information in the Subsequent
Financing Notice becomes publicly disclosed or on the 10th day after receipt of the Subsequent Financing Notice.


 


(c) Any Holder
desiring to participate in such Subsequent Financing must provide written notice to the Company by 6:30 am (New York City time)
on the Trading Day following the date on which the Subsequent Financing Notice is delivered to such Holder (the “Notice
Termination Time”) that such Holder is willing to participate in the Subsequent Financing, the amount of such Holder’s
participation, and representing and warranting that such Holder has such funds ready, willing, and available for investment on
the terms set forth in the Subsequent Financing Notice. If the Company receives no such notice from a Holder as of such Notice
Termination Time, such Holder shall be deemed to have notified the Company that it does not elect to participate in such Subsequent
Financing.


 


(d) If, by
the Notice Termination Time, notifications by the Holder and all Other Holders of their willingness to participate in the Subsequent
Financing (or to cause their designees to participate) is, in the aggregate, less than the Participation Maximum of the Subsequent
Financing, then the Company may effect the remaining portion of such Subsequent Financing on the terms and with the Persons set
forth in the Subsequent Financing Notice.


 


(e) If, by
the Notice Termination Time, the Company receives responses to a Subsequent Financing Notice from the Holder and all Other Holders
seeking to purchase more than the aggregate amount of the Participation Maximum, the Holder and each such Other Holder shall have
the right to purchase its Pro Rata Portion (as set forth on the signature page hereto) of the Participation Maximum. 


 


(f) The Company
must provide the Holder with a second Subsequent Financing Notice, and the Holder will again have the right of participation set
forth above in this Section 2.2, if the definitive agreement related to the initial Subsequent Financing Notice is not entered
into for any reason on the terms set forth in such Subsequent Financing Notice within two (2) Trading Days after the date of delivery
of the initial Subsequent Financing Notice.


 


(g) The Company
and each Holder agree that if any Holder elects to participate in a Subsequent Financing, neither the subsequent placement with
respect to such Subsequent Financing nor any other transaction documents related thereto (collectively, the “Subsequent Placement
Documents”) shall include any term or provision whereby such Holder shall be required to agree to any restrictions on trading
as to any securities of the Company (other than as required by law).


 



    2


     


    




 


(h) Notwithstanding
the foregoing, this Section 4.11 shall not apply to (x) the sales of the Company’s common stock by any method permitted by
law deemed to be an “at the market” offering as defined in Rule 415(a)(4) of the Securities Act, including without
limitation sales made directly on the Nasdaq Capital Market, on any other existing trading market for the Common Stock or to or
through a market maker; and (y) any private or registered offering to any “non-U.S. Person” as defined in the Regulation
S of the Securities Act.


 


Section 2.3 Leak-Out


 


(a) The Holder
agrees solely with the Company that from the date hereof (the “Effective Date”) and ending at 4:00 pm (New York City
time) on April 8, 2021 (such period, the “Restricted Period”), neither the Holder, nor any affiliate of such
Holder which (x) had or has knowledge of the transactions contemplated by this Agreement, (y) has or shares discretion relating
to such Holder’s investments or trading or information concerning such Holder’s investments, including in respect of
the Securities, or (z) is subject to such Holder’s review or input concerning such affiliate’s investments or trading
(together, the “Holder’s Trading Affiliates”), collectively, shall sell, dispose or otherwise transfer,
directly or indirectly, (including, without limitation, any sales, short sales, swaps or any derivative transactions that would
be equivalent to any sales or short positions) on any Trading Day during the Restricted Period (any such date, a “Date
of Determination”), shares of Common Stock of the Company, or shares of Common Stock of the Company underlying any convertible
securities or options, held by the Holder on the date hereof, including, without limitations, the Securities (collectively, the
“Restricted Securities”), in an amount representing more than 10.0% of the daily trading volume of Common Stock
as reported by Bloomberg, LP for each applicable Date of Determination (“Leak-Out Percentage”).


 


(b) Notwithstanding
anything herein to the contrary, during the Restricted Period, the Holder may, directly or indirectly, sell or transfer all, but
not less than all, of any Restricted Securities to any Person (an “Assignee”) in a transaction which does not
need to be reported on the consolidated tape on the Trading Market (as defined in the Warrants), without complying with (or otherwise
limited by) the restrictions set forth in this Leak-Out Agreement; provided, that as a condition to any such sale or transfer an
authorized signatory of the Company and such Assignee duly execute and deliver a leak-out agreement in the form of Section 2.3
of this Agreement.


 


Section 2.4 Public
Disclosure. Prior to 9:30 A.M. on March 10, 2021, the Company shall issue a press release disclosing the material terms of
the transactions contemplated hereby and within the time required by the laws file a Current Report on Form 8-K with the Commission,
which shall include a form of this Agreement (the “8-K Filing”). Furthermore, the Company shall file a prospectus
supplement to the Registration Statement with the Securities and Exchange Commission disclosing the Warrant Exercise prior to 9:30
A. M. on March 10, 2021 . From and after the issuance of the press release, the Company represents to the Holder that it shall
not be in possession of any material, nonpublic information received from the Company, any of its subsidiaries (for purposes of
this Agreement, as defined in Rule 405 under the Securities Act) or any of their respective officers, directors, employees or agents
that is not disclosed in press release. In addition, effective upon the issuance of the press release, the Company acknowledges
and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company,
any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the
Holder or any of its affiliates, on the other hand, shall terminate.


 


Section 2.5 Fundamental
Transactions. From the date hereof until the six (6) month anniversary of the date hereof, in the event the Company enters into
or be party to a Fundamental Transaction as defined in the Original Warrants, and the Black Scholes Value of the Original Warrants
is greater than the proceeds (“Proceeds”) of the Exercised Shares sold by the Holder in the public market, the Company
shall pay the Holder the difference between Black Scholes Value of the Original Warrant and the Proceeds. If the Black Scholes
Value of the Original Warrant is equal or less than the Proceeds, the Company will not be obligated to pay anything to the Holder.
The Holder shall provide trading record demonstrating the Proceeds if it makes a request pursuant to this section.


 



    3


     


    




 


Section 2.5 Subsequent
Placements. From the date hereof until the 30 day anniversary of the date hereof, neither the Company nor any subsidiary of the
Company shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common
Stock or any securities of the Company or any subsidiaries which would entitle the holder thereof to acquire at any time shares
of Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common
Stock, or (ii) file any registration statement, or amendment or supplement thereto, with the Commission other than those filed
pursuant to this agreement or Other Warrant Exercised Agreements executed by Other Holders. Notwithstanding the foregoing, the
foregoing shall not apply in respect of an Exempt Issuance. “Exempt Issuance” means the issuance of (a) shares of Common
Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such
purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee
directors established for such purpose for services rendered to the Company, provided, however, such issuance shall not exceed
ten percent (10%) of the shares of Common Stock issued and outstanding as of the date hereof, (b) securities upon the exercise
or exchange of or conversion of any securities exercisable or exchangeable for or convertible into shares of Common Stock issued
and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith, and provided that any such issuance shall
only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or
an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.


 


ARTICLE III


REPRESENTATIONS AND WARRANTIES


 


Section 3.1 Representations
and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that
as of the date of its execution of this Agreement:


 


(a) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by
all necessary action on the part of such Company and no further action is required by such Company, its board of directors or its
shareholders in connection therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with
the terms hereof will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.


 


(b) Organization.
The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Delaware.


 


(c) Intentionally
Left Blank


 


(d) No
Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of
the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien upon any
of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument
(evidencing Company debt or otherwise) or other material understanding to which the Company is a party or by which any property
or asset of the Company is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including
federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.


 



    4


     


    




 


(e) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Holder or any of its agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the
Holder will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Holder regarding the Company and its subsidiaries, their respective businesses
and the transactions contemplated hereby, including but not limited to the disclosure set forth in the SEC Reports, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements made therein, in light of the circumstances under which they were made, not misleading. As used herein, “SEC
Reports” means all reports, schedules, forms, statements and other documents required to be filed by the Company with
the Commission pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended, including all exhibits
included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein.


 


(f) Registration
Statement. The Exercised Shares will be registered in a prospectus supplement to the Registration Statement to be filed with the
Commission prior to 9:30 A.M. on March 10, 2021 and, when the prospectus supplement is filed, the Company knows of no reason why
such registration statement shall not remain effective for the foreseeable future. The Company shall use commercially reasonable
efforts to keep the Registration Statement effective and available for use by the Holder until all Exercised Shares issuable hereunder
are sold by the Holder.


 


 


Section 3.2 Representations
and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company
that as of the date of its execution of this Agreement:


 


(a) Due
Authorization. The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the consummation
by it of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and (ii) this Agreement
has been duly executed and delivered by the Holder and constitutes the valid and binding obligation of the Holder, enforceable
against it in accordance with its terms.


 


(b) No
Conflicts. The execution, delivery and performance of this Agreement by the Holder and the consummation by the Holder of the
transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Holder’s organizational
or charter documents, or (ii) conflict with or result in a violation of any agreement, law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority which would interfere with the ability of the Holder
to perform its obligations under this Agreement.


 


(c) Access
to Information. The Holder acknowledges that it has had the opportunity to review this Agreement and the SEC Reports and has
been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the exercise of the Original Warrants and the merits and risks of investing
in the Exercised Shares underlying the Original Warrants; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)
the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or
expense that is necessary to make an informed investment decision with respect to the investment. The Holder acknowledges and agrees
that neither the Placement Agent nor any Affiliate of the Placement Agent has provided the Holder with any information or advice
with respect to the Original Warrants or the Exercised Shares nor is such information or advice necessary or desired. Neither the
Placement Agent nor any Affiliate of the Placement Agent has made or makes any representation as to the Company or the quality
of the Original Warrants or the Exercised Shares, and the Placement Agent and any Affiliate of the Placement Agent may have acquired
non-public information with respect to the Company which the Holder agrees need not be provided to it. In connection with the issuance
of the Exercised Shares to the Holder, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or
fiduciary to the Holder.


 



    5


     


    




 


(d) Holder
Status. The Holder is an “accredited investor” as defined in Rule 501 under the Securities Act.


  


ARTICLE IV


MISCELLANEOUS


 


Section 4.1  Reserved


 


Section 4.2 Other
Warrant Exercised Agreement. The Company acknowledges and agrees that the obligations of the Holder under this Agreement are
several and not joint with the obligations of any Other Holder under any other agreement related to the exercise of such Other
Holder’s Original Warrants (“Other Warrant Exercised Agreement”), and the Holder shall not be responsible
in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercised Agreement. Nothing
contained in this Agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the
Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder
and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated
by this Agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with
respect to such obligations or the transactions contemplated by this Agreement or any Other Warrant Exercised Agreement. The Company
and the Holder confirms that the Holder has independently participated in the negotiation of the transactions contemplated hereby
with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce their rights,
including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any Other Holder to
be joined as an additional party in any proceeding for such purpose.


 


Section 4.3 Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be made by email
to the email address of Holder set forth on Holder’s signature page.


 


Section 4.4 Survival.
All warranties and representations (as of the date such warranties and representations were made) made herein or in any certificate
or other instrument delivered by any party hereto or on its behalf under this Agreement shall be considered to have been relied
upon by the parties hereto and shall survive the issuance of the Exercised Shares. This Agreement shall inure to the benefit of
and be binding upon the successors and permitted assigns of each of the parties; provided, however, that no party may assign this
Agreement or the obligations and rights of such party hereunder without the prior written consent of the other parties hereto.


 


Section 4.5 Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.


 


Section 4.6 Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.


 


Section 4.7 Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
pursuant to the Governing Law provision in Section 7.4 of the Original Warrants.


 



    6


     


    




 


Section 4.8 Entire
Agreement. The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.


 


Section 4.9 Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


Section 4.10 Fees
and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and
all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this
Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the
delivery of any Exercised Shares.


 


Section 4.11 Intentionally
Omitted.


 


Section 4.12 Beneficial
Ownership Limitation. The parties hereby agree that the Beneficial Ownership Limitation for the Original Warrant for purposes
of this agreement is [9.99%]/ [4.99%]1.


 





*******************





 






		11	4.99% for Introcoastal




 




    7


     


    

 


IN WITNESS WHEREOF,
the undersigned have executed this Waiver and Warrant Exercise Agreement as of the date first written above.


 


	COMPANY:  	 
	 	 
	TD HOLDINGS, INC.  	 
	 	 
	By: 		 
	Name: 	Renmei Ouyang	 
	Title: 	Chief Executive Officer	 



 


Bank Account and Wire Instructions:


  




    8


     


    

 


[HOLDER SIGNATURE PAGE TO TD HOLDINGS,
INC. 


WAIVER AND WARRANT EXERCISE AGREEMENT]


 


IN WITNESS WHEREOF, the undersigned have
caused this Waiver and Warrant Exercise Agreement to be duly executed by their respective authorized signatories as of the date
first indicated above.


 


Name of Holder: ____________________________________________


 


Signature of Authorized Signatory of Holder: ____________________________________________


 


Name of Authorized Signatory: ____________________________________________


 


Title of Authorized Signatory: ____________________________________________


 


Email Address of Holder: ____________________________________________


 


Number of Warrant Shares underlying the April Warrants: ___________________


 


Number of Warrant Shares underlying the May Warrants: ___________________


 


	Exercised Shares for the April Warrants:               


 


Exercised Shares for the May Warrants:                


 


Participation Pro Rata Portion: _____


 


DWAC Instructions for Exercised Shares to be issued upon exercise
of Original Warrants: __________________


 




    9